Pacira Shares Rise 44.40% After Viatris Announces Cash Acquisition

The October 8 move

Pacira BioSciences shares closed at $36.39 on October 8, 2026, up $11.19, or 44.40%, from the previous close of $25.20. That day, Viatris and Pacira announced a definitive agreement for Viatris to acquire Pacira for $36.50 per share in cash. The offer exceeded the October 7 closing price by $11.30, or approximately 44.84%. The announcement is the documented catalyst for the move; the available record does not isolate the contribution of any other factor.

Pacira’s October 8 close was $0.11, or approximately 0.30%, below the offered cash consideration. That small gap shows how closely the stock traded to the proposed purchase price by the end of the session. It does not establish a probability that the transaction will fail. Closing conditions, the time until payment and other factors can affect a stock’s pre-closing price.

Trading activity also changed sharply. Stock Analysis reports volume of 28,901,928 Pacira shares on October 8, compared with 802,729 on October 7. Those figures document substantially heavier trading alongside the price increase. They do not identify who bought or sold shares, or why individual investors traded.

What the agreement provides

The agreement disclosed by Pacira names Viatris, Pacira and Viatris subsidiary Peach Purchaser Sub Inc. as parties. The companies announced an aggregate equity value of $1.65 billion. A specified cash payment per share gives investors a transaction value against which to compare Pacira’s trading price. Completion remains subject to the agreement’s conditions, so the October 8 market price was a price for shares before the proposed acquisition had closed.

The transaction is structured as a tender offer. The agreement calls for that offer to begin no more than 15 business days after October 8. Completion requires, among other conditions, enough shares to be tendered to exceed 50% of Pacira’s outstanding shares and expiration or termination of the applicable U.S. antitrust waiting period. Following a successful tender offer, a second-step merger would acquire remaining eligible shares for the same consideration without a separate stockholder vote.

Both companies’ boards unanimously approved the transaction, and Pacira’s board recommends that stockholders tender their shares. The companies expect to close by the end of 2026, an expected timetable rather than a guaranteed date. If the acquisition closes, Pacira would become a wholly owned Viatris subsidiary and PCRX would cease trading on Nasdaq. Viatris says it expects to fund the purchase primarily with excess cash and the remainder with short-term borrowings.

Business context and remaining conditions

Pacira markets EXPAREL for acute postsurgical pain and ZILRETTA for osteoarthritis knee pain. In their joint announcement, the companies reported approximately $746 million in Pacira revenue and $177 million in adjusted EBITDA for the twelve months ended June 30, 2026. Pacira’s products and commercial capabilities are part of Viatris’s stated rationale for the purchase. Viatris’s expectations for accretion, product synergies and wider international reach are management forecasts, not results established by the announcement.

The next transaction filings should provide more detail for shareholders weighing the tender offer. Those documents include the tender-offer filing and Pacira’s subsequent Schedule 14D-9, which will set out its recommendation. The agreement provides for a $62 million fee payable by Pacira under specified termination circumstances, including acceptance of a superior offer. That provision does not establish that Pacira has received another bid.

Viatris has scheduled its third-quarter results call for November 5, 2026, and says it will discuss the acquisition then. For PCRX holders, the immediate questions are whether the majority-share tender threshold and antitrust condition will be satisfied, and when the proposed cash payment might occur. The October 8 closing price records the market’s response to an announced agreement; it does not resolve those remaining steps or verify the companies’ projected financial benefits.

MacroShed Markets is informational analysis, not investment advice.